Source and scope
This summary is bounded to the recommendations, population and decisions covered by Management of acne: Canadian clinical practice guideline. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian acne guideline
Source-attributed clinical priorities
- Grade inflammatory and comedonal acne, scarring, pigment change and psychosocial impact and review acne-promoting medicines or products.
- Use topical combination treatment for most mild or moderate disease and add systemic therapy only for an appropriate phenotype and duration.
- Prevent pregnancy exposure to teratogenic retinoids and refer nodulocystic, scarring, refractory or severely distressing acne.
- Document scarring and psychological distress because either may justify earlier systemic or specialist care.
sources for this section:Canadian acne guideline
Practical assessment and management workflow
1
Grade comedones, inflammatory lesions, nodules, distribution, pigment change and scarring.
2
Review pregnancy possibility, skin products, friction and acne-promoting medicines.
3
Select complementary topical agents and explain application, irritation reduction and the time needed for response.
4
Review after an adequate trial and add oral or specialist treatment only when severity and risk warrant it.
sources for this section:Canadian acne guideline
Safety, red flags and urgent escalation
- Prevent pregnancy exposure to oral and topical retinoids according to Canadian product requirements.
- Severe nodulocystic or fulminant acne needs prompt dermatology assessment.
- Avoid prolonged antibiotic monotherapy; combine and limit use to reduce resistance.
sources for this section:Canadian acne guideline
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian acne guideline
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian acne guideline
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Acne Clinical Practice Guideline PanelManagement of acne: Canadian clinical practice guidelineaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.